Comparative Pharmacology
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus TRANMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus TRANMEP.
BUSPIRONE HYDROCHLORIDE vs TRANMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, primarily in the raphe nuclei and hippocampus; also exhibits antagonist properties at presynaptic 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, resulting in decreased serotonergic activity. Additionally, it has moderate affinity for dopamine D2 receptors (antagonist) and alpha2-adrenergic receptors.
Tianeptine is a selective serotonin reuptake enhancer (SSRE) and also modulates glutamatergic signaling via AMPA and NMDA receptors. It increases serotonin transport in presynaptic neurons and enhances neuroplasticity.
Initial dose: 7.5 mg orally twice daily; may increase by 2.5-5 mg every 2-3 days to a target dose of 15-30 mg/day in divided doses (2-3 times daily). Maximum dose: 60 mg/day divided twice daily.
50 mg orally every 8 hours, may increase to 100 mg every 8 hours if needed.
None Documented
None Documented
2-3 hours terminal half-life; clinical context: requires multiple daily dosing (3 times daily) due to short half-life; no active metabolites prolonging effect.
4-6 hours in adults; prolonged in hepatic impairment (up to 12 hours) and elderly.
Renal: 29-63% (as metabolites; <1% unchanged); Fecal: 18-38%; Hepatic metabolism primarily via CYP3A4; total clearance 1.5-3.5 L/h/kg.
Renal: ~60% as unchanged drug, biliary/fecal: ~30% as metabolites, remainder as unchanged drug.
Category A/B
Category C
Anxiolytic
Anxiolytic